These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 2407709)

  • 1. 6-(substituted methylene)penems, potent broad spectrum inhibitors of bacterial beta-lactamase. II. Racemic furyl and thienyl derivatives.
    Broom NJ; Coleman K; Hunter PA; Osborne NF
    J Antibiot (Tokyo); 1990 Jan; 43(1):76-82. PubMed ID: 2407709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 6-(substituted methylene)penems, potent broad spectrum inhibitors of bacterial beta-lactamase. III. Structure-activity relationships of the 5-membered heterocyclic derivatives.
    Bennett I; Broom NJ; Bruton G; Calvert S; Clarke BP; Coleman K; Edmondson R; Edwards P; Jones D; Osborne NF
    J Antibiot (Tokyo); 1991 Mar; 44(3):331-7. PubMed ID: 2026558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 6-(substituted methylene)penems, potent broad spectrum inhibitors of bacterial beta-lactamase. I. Racemic 6-ethylidenepenems.
    Basker MJ; Osborne NF
    J Antibiot (Tokyo); 1990 Jan; 43(1):70-5. PubMed ID: 2307631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Study of in vitro activity of 3 cephalosporins and their combination with 2 beta-lactamase inhibitors against 4 enterobacteria strains producing extended spectrum beta-lactamase].
    Cattoen C; Duflos D; Bouillet L; Chatelain C; Mazars E
    Pathol Biol (Paris); 1997 May; 45(5):425-9. PubMed ID: 9296097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Susceptibility of clinical isolates to expanded-spectrum beta-lactams alone and in the presence of beta-lactamase inhibitors.
    Qadri SM; Ueno Y; Cunha BA
    Chemotherapy; 1996; 42(5):334-42. PubMed ID: 8874972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High frequency of beta-lactam susceptibility in CTX-M-type extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae, Escherichia coli and Proteus mirabilis according to the new CLSI recommendations.
    de Oliveira KR; de Freitas AL; Willers DM; Barth AL; Zavascki AP
    J Antimicrob Chemother; 2010 Nov; 65(11):2481-3. PubMed ID: 20846935
    [No Abstract]   [Full Text] [Related]  

  • 7. 6-(substituted methylene)penems, potent broad spectrum inhibitors of bacterial beta-lactamase. V. Chiral 1,2,3-triazolyl derivatives.
    Bennett IS; Brooks G; Broom NJ; Calvert SH; Coleman K; François I
    J Antibiot (Tokyo); 1991 Sep; 44(9):969-78. PubMed ID: 1938620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 6-(substituted methylene)penems, potent broad spectrum inhibitors of bacterial beta-lactamase. IV. Kidney stability, serum binding and additional biological evaluation of racemic derivatives.
    Bennett IS; Broom NJ; Coleman K; Coulton S; Edwards PD; Francois I; Griffin DR; Osborne NF; Woodall PM
    J Antibiot (Tokyo); 1991 Mar; 44(3):338-43. PubMed ID: 2026559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bactericidal activity of ertapenem against major intra-abdominal pathogens.
    Borbone S; Cascone C; Santagati M; Mezzatesta ML; Stefani S
    Int J Antimicrob Agents; 2006 Nov; 28(5):396-401. PubMed ID: 17045463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Beta-lactamase producers and other bacteria: which ones to take into consideration and when? The concept of beta-lactamase inhibitor].
    Jarlier V
    Presse Med; 1998 Sep; 27 Suppl 4():17-8. PubMed ID: 9798480
    [No Abstract]   [Full Text] [Related]  

  • 11. 6-Acetylmethylenepenicillanic acid (Ro 15-1903), a potent beta-lactamase inhibitor. II. Antibacterial properties.
    Angehrn P; Arisawa M
    J Antibiot (Tokyo); 1982 Nov; 35(11):1584-9. PubMed ID: 6298168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-activity relationship of 6-methylidene penems bearing tricyclic heterocycles as broad-spectrum beta-lactamase inhibitors: crystallographic structures show unexpected binding of 1,4-thiazepine intermediates.
    Venkatesan AM; Gu Y; Dos Santos O; Abe T; Agarwal A; Yang Y; Petersen PJ; Weiss WJ; Mansour TS; Nukaga M; Hujer AM; Bonomo RA; Knox JR
    J Med Chem; 2004 Dec; 47(26):6556-68. PubMed ID: 15588091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activities of the frog skin peptide, ascaphin-8 and its lysine-substituted analogs against clinical isolates of extended-spectrum beta-lactamase (ESBL) producing bacteria.
    Eley A; Ibrahim M; Kurdi SE; Conlon JM
    Peptides; 2008 Jan; 29(1):25-30. PubMed ID: 18068868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Drug sensitivity of bacteria isolated from clinical samples (author's transl)].
    Sawatari K; Mochida C; Iori F; Hayashi A; Nasu M
    Jpn J Antibiot; 1980 Jan; 33(1):87-96. PubMed ID: 6990050
    [No Abstract]   [Full Text] [Related]  

  • 15. 5,6-Cis-penems: broad-spectrum anti-methicillin-resistant Staphylococcus aureus beta-lactam antibiotics.
    Ishiguro M; Tanaka R; Namikawa K; Nasu T; Inoue H; Nakatsuka T; Oyama Y; Imajo S
    J Med Chem; 1997 Jul; 40(14):2126-32. PubMed ID: 9216830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beta-lactamase inhibitory activities and synergistic effects of 5,6-cis-carbapenem antibiotics.
    Okonogi K; Harada S; Shinagawa S; Imada A; Kuno M
    J Antibiot (Tokyo); 1982 Aug; 35(8):963-71. PubMed ID: 6982889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [In vitro antibacterial activity of a new parenteral penem, sulopenem].
    Yoshida T; Tateda E; Hiramatsu K; Yokota T
    Jpn J Antibiot; 1996 Apr; 49(4):324-37. PubMed ID: 8786624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparison between the activity of 2 amino-glycoside antibiotics, tobramycin and gentamicin on gram negative bacteria in vitro].
    De Rosa F; Tassi C; Stagni GR
    Ann Sclavo; 1974; 16(1):65-72. PubMed ID: 4214247
    [No Abstract]   [Full Text] [Related]  

  • 19. Use of penicillinase-resistant penicillins to increase the susceptibility of gram-negative bacteria to antibiotics.
    Farrar WE; O'Dell NM; Krause JM
    Ann Intern Med; 1967 Oct; 67(4):733-43. PubMed ID: 4862467
    [No Abstract]   [Full Text] [Related]  

  • 20. In-vitro anti-microbial susceptibility of clinical isolates of pathogenic bacteria to ten antibiotics including phosphomycin.
    Eke PI; Rotimi VO
    Afr J Med Med Sci; 1987 Mar; 16(1):1-8. PubMed ID: 3037870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.